Speakers | Kisaco Research

Speakers

Animal Health, Nutrition and Technology Innovation Europe 2024
4-6 March, 2024
London, UK
  • Author:

    Rob Kelly

    Senior Vice President, Commercial Leader for EURAM Region
    MSD Animal Health

    Rob Kelly

    Senior Vice President, Commercial Leader for EURAM Region
    MSD Animal Health
  • Author:

    Jamie Brannan

    EVP and President International Operations and Aquaculture
    Zoetis

    Jamie Brannan

    EVP and President International Operations and Aquaculture
    Zoetis
  • Author:

    Ranveer Chandra

    Chief Technology Officer of Agri-Food
    Microsoft

    Ranveer Chandra

    Chief Technology Officer of Agri-Food
    Microsoft
  • Author:

    Chris Boyle

    Senior Managing Associate
    Sidley Austin LLP

    Chris Boyle

    Senior Managing Associate
    Sidley Austin LLP
  • Author:

    Ellen de Brabander

    Executive Vice President R&D and Innovation
    Elanco

    Ellen de Brabander

    Executive Vice President R&D and Innovation
    Elanco
  • Author:

    Aaron Schacht

    CEO
    BiomEdit

    Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

    Aaron Schacht

    CEO
    BiomEdit

    Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

  • Author:

    Alan Mackay

    Executive Partner and Founder
    GHO Capital

    Alan Mackay

    Executive Partner and Founder
    GHO Capital
  • Author:

    Emily Don

    Head of Sustainability
    Avara Foods

    Emily Don

    Head of Sustainability
    Avara Foods
  • Author:

    Kim Müller Christensen

    Global Commercial Senior Manager – Plant Health
    CHR-Hansen, Denmark

    Kim Müller Christensen

    Global Commercial Senior Manager – Plant Health
    CHR-Hansen, Denmark
  • Author:

    Candise Goodwin

    Founder
    Outlier Advisors

    Candise Goodwin

    Founder
    Outlier Advisors
  • Author:

    Beatrice Vos, PhD

    Partner
    Stonehaven Cozmix Group (and CEO @ SC Transactions AG)

    Beatrice Vos, PhD

    Partner
    Stonehaven Cozmix Group (and CEO @ SC Transactions AG)
  • Author:

    Bruce Truman

    President and Founder
    BLT Technology & Innovation Group

    Bruce Truman

    President and Founder
    BLT Technology & Innovation Group
  • Author:

    Professor Michael Lee

    Deputy Vice Chancellor
    Harper Adams University

    Professor Michael Lee

    Deputy Vice Chancellor
    Harper Adams University
  • Author:

    Charles Hoare

    Managing Director, Head of European Healthcare M&A
    Stifel

    Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

    He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

    Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

    Charles Hoare

    Managing Director, Head of European Healthcare M&A
    Stifel

    Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

    He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

    Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

  • Author:

    Brian Quinn

    CEO
    WellFish Diagnostics

    Brian Quinn

    CEO
    WellFish Diagnostics
  • Author:

    Dieter Schillinger

    Ex - Deputy Director General Biosciences
    International Livestock Research Institute (ILRI)

    Dieter Schillinger

    Ex - Deputy Director General Biosciences
    International Livestock Research Institute (ILRI)
  • Author:

    Charlie Barton

    Co-Founder
    Virtual Recall

    Charlie Barton

    Co-Founder
    Virtual Recall
  • Author:

    Dave Ross

    Chief Executive Officer
    Agri-EPI Centre Ltd

    Dave Ross

    Chief Executive Officer
    Agri-EPI Centre Ltd
  • Author:

    David Tinsley

    Managing Director
    MWI

    David Tinsley

    Managing Director
    MWI
  • Author:

    Deborah Dullen

    President and CEO
    BioTraceIT

    Deborah Dullen

    President and CEO
    BioTraceIT
  • Author:

    Greg Blair

    Vice President of Business Development
    Zomedica

    Greg Blair

    Vice President of Business Development
    Zomedica
  • Author:

    Adrienne Woodward

    Manager of Swine – Specialty Product Research
    United Animal Health

    Adrienne Woodward

    Manager of Swine – Specialty Product Research
    United Animal Health
  • Author:

    Julia Stephanus

    Partner
    Borealis Ventures

    Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

    Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

    As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

    As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

    Julia Stephanus

    Partner
    Borealis Ventures

    Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

    Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

    As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

    As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

  • Author:

    Karolina Zapadka

    Investor
    Park Walk Advisors

    Karolina Zapadka

    Investor
    Park Walk Advisors
  • Author:

    Julie Lawless

    President
    Lawless Strategic Communications

    Julie Lawless

    President
    Lawless Strategic Communications
  • Author:

    Ken Bowman

    President
    KVP International

    Ken Bowman

    President
    KVP International
  • Author:

    Jeroen van de Ven

    Lead, Global Marketing and Commercial Services
    MSD Animal Health

    Jeroen van de Ven

    Lead, Global Marketing and Commercial Services
    MSD Animal Health
  • Author:

    Hannah McIver

    CEO & President
    Microsintesis

    Hannah McIver

    CEO & President
    Microsintesis
  • Author:

    Linda Dixon

    Group Leader, African Swine Fever Virus
    The Pirbright Institute

    Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

    Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions. 

    In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.

    In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator. 

    Linda Dixon

    Group Leader, African Swine Fever Virus
    The Pirbright Institute

    Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.

    Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions. 

    In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.

    In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator. 

  • Author:

    Linda Rhodes

    VMD, PhD, Independent and ex-CSO
    Independent Animal Health

    Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

    Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

    Linda Rhodes

    VMD, PhD, Independent and ex-CSO
    Independent Animal Health

    Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

    Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

  • Author:

    Louise Grubb

    CEO & Co-Founder
    TriviumVet

    Louise Grubb

    CEO & Co-Founder
    TriviumVet
  • Author:

    Matt Dobbs

    Global Chief Medical Officer
    Destination Pet

    Matt Dobbs

    Global Chief Medical Officer
    Destination Pet
  • Author:

    Professor Maxime Madder

    Director Biologics and Infectious Diseases
    Clinglobal

    Professor Maxime Madder

    Director Biologics and Infectious Diseases
    Clinglobal
  • Author:

    Paul Dick

    President
    Paul Dick & Associates

    Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

    While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

    His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

    Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

    In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

    Paul Dick

    President
    Paul Dick & Associates

    Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

    While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

    His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

    Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

    In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

  • Author:

    Alan White

    Commercial Relations Director
    MWI Animal Health

    Alan White

    Commercial Relations Director
    MWI Animal Health
  • Author:

    Simon Doherty

    Associate Fellow
    Queen’s University Belfast

    Simon Doherty

    Associate Fellow
    Queen’s University Belfast
  • Author:

    Spencer Swayze

    Managing Director
    Paine Schwartz Partners, LLC

    Spencer Swayze

    Managing Director
    Paine Schwartz Partners, LLC
  • Author:

    Sven Arnouts

    Business Development
    Ghent University

    Sven Arnouts

    Business Development
    Ghent University
  • Author:

    Daniel Oliver

    CEO and Founder
    Rejuvenate Bio

    Daniel Oliver

    CEO and Founder
    Rejuvenate Bio
  • Author:

    Douglas Hutchison FRSE FRCVS NXD

    Non-Executive Director
    Hallmarq Veterinary Imaging Ltd

    Douglas Hutchison FRSE FRCVS NXD

    Non-Executive Director
    Hallmarq Veterinary Imaging Ltd
  • Author:

    James Ede

    Group Sustainability Lead – Starches, Sweeteners, and Texturisers
    Cargill

    James Ede

    Group Sustainability Lead – Starches, Sweeteners, and Texturisers
    Cargill
  • Author:

    Marie-Paul Lachaud

    Referent Animal Health R&D
    One Health Pharma

    Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

    Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

    From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000. 

    Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders. 

    She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

     

    Marie-Paul Lachaud

    Referent Animal Health R&D
    One Health Pharma

    Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

    Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

    From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000. 

    Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders. 

    She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

     

  • Author:

    Wendy Furness

    Director & Founder
    Animal Health Angels

    Wendy Furness

    Director & Founder
    Animal Health Angels